The signature of SARS-CoV-2-related genes predicts the immune therapeutic response and prognosis in breast cancer.
Bioinformatics
Breast cancer
COVID-19
Prognosis
SARS-CoV-2
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
30
01
2024
accepted:
15
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an exceptionally contagious single-stranded RNA virus with a strong positive contagion. The COVID-19 pandemic refers to the swift worldwide dissemination of SARS-CoV-2 infection, which began in late 2019. The COVID-19 epidemic has disrupted many cancer treatments. A few reports indicate that the prevalence of SARS-CoV-2 has disrupted the treatment of breast cancer patients (BCs). However, the role of SARS-CoV-2 in the occurrence and prognosis of BC has not been elucidated. Here, we applied bioinformatics to construct a prognostic signature of SARS-CoV-2-related genes (SCRGs). Specifically, weighted gene co-expression network analysis (WGCNA) was utilized to extract co-expressed genes of differentially expressed genes (DEGs) in breast cancer and SCRGs. Then, we utilized the least absolute shrinkage and selection operator (LASSO) algorithm and univariate regression analysis to screen out three hub genes (DCTPP1, CLIP4 and ANO6) and constructed a risk score model. We further analyzed tumor immune invasion, HLA-related genes, immune checkpoint inhibitors (ICIs), and sensitivity to anticancer drugs in different SARS-CoV-2 related risk subgroups. In addition, we have developed a nomination map to expand clinical applicability. The results of our study indicate that BCs with a high-risk score are linked to negative outcomes, lower immune scores, and reduced responsiveness to anticancer medications. This suggests that the SARS-CoV-2 related signature could be used to guide prognosis assessment and treatment decisions for BCs.
Identifiants
pubmed: 39482662
doi: 10.1186/s12920-024-02032-0
pii: 10.1186/s12920-024-02032-0
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Informations de copyright
© 2024. The Author(s).
Références
Moris D, Tsilimigras DI, Schizas D. Cancer and COVID-19. Lancet. 2020;396(10257):1066. https://doi.org/10.1016/S0140-6736(20)32069-9 .
doi: 10.1016/S0140-6736(20)32069-9
pubmed: 33038962
pmcid: 7544492
Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic opportunities and challenges. Theranostics. 2021;11(2):731–53. https://doi.org/10.7150/thno.51471 .
doi: 10.7150/thno.51471
pubmed: 33391502
pmcid: 7738845
Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, Painter CA. COVID-19 and Cancer: current challenges and perspectives. Cancer Cell. 2020;38(5):629–46. https://doi.org/10.1016/j.ccell.2020.09.018 .
doi: 10.1016/j.ccell.2020.09.018
pubmed: 33049215
pmcid: 7528740
Ren X, Wen W, Fan X et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas [published correction appears in Cell. 2021;184(23):5838. https://doi.org/10.1016/j.cell.2021.10 .023]. Cell. 2021;184(7):1895–1913.e19. doi:10.1016/j.cell.2021.01.053.
Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–4. https://doi.org/10.1038/s41591-020-0901-9 .
doi: 10.1038/s41591-020-0901-9
pubmed: 32398875
Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50. https://doi.org/10.1016/S0140-6736(16)31891-8 .
doi: 10.1016/S0140-6736(16)31891-8
pubmed: 27865536
Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708–28. https://doi.org/10.1016/j.cell.2023.01.040 .
doi: 10.1016/j.cell.2023.01.040
pubmed: 36931265
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41. https://doi.org/10.3322/caac.21754 .
doi: 10.3322/caac.21754
pubmed: 36190501
Petropoulou Z, Arkadopoulos N, Michalopoulos NV. Breast Cancer and COVID-19: challenges in Surgical Management. Cancers (Basel). 2022;14(21):5360. https://doi.org/10.3390/cancers14215360 .
doi: 10.3390/cancers14215360
pubmed: 36358779
Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium. The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 2021;151:106585. https://doi.org/10.1016/j.ypmed.2021.106585 .
doi: 10.1016/j.ypmed.2021.106585
Tonneson JE, et al. Impact of the COVID-19 pandemic on breast Cancer stage at diagnosis, presentation, and Patient Management. Annals Surg Oncol vol. 2022;29(4):2231–9.
doi: 10.1245/s10434-021-11088-6
Jiang F et al. Dec. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma. Cells vol. 11,24 3997. 10 2022, https://doi.org/10.3390/cells11243997
Huang Y, Chen S, Xiao L, Qin W, Li L, Wang Y, Ma L, Yuan X. A Novel Prognostic signature for Survival Prediction and Immune Implication based on SARS-CoV-2-Related genes in kidney renal clear cell carcinoma. Front Bioeng Biotechnol. 2022;9:744659. https://doi.org/10.3389/fbioe.2021.744659 .
doi: 10.3389/fbioe.2021.744659
pubmed: 35141213
pmcid: 8819071
Ren Q, Zhang P, Zhang S, Chen W, Chi H, Wang W, Zhang W, Lin H, Yu Y. A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer. Aging. 2023;15(19):10501–23. https://doi.org/10.18632/aging.205090 .
doi: 10.18632/aging.205090
pubmed: 37812215
pmcid: 10599722
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7 .
doi: 10.1186/1471-2105-14-7
pubmed: 23323831
pmcid: 3618321
Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468. https://doi.org/10.1371/journal.pone.0107468 .
doi: 10.1371/journal.pone.0107468
pubmed: 25229481
pmcid: 4167990
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032 .
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). 2021 [updated February 16, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html . Accessed 20 January 2022.
Brito-Dellan N, Tsoukalas N, Font C. Thrombosis, cancer, and COVID-19. Support Care Cancer. 2022;30(10):8491–500. https://doi.org/10.1007/s00520-022-07098-z .
doi: 10.1007/s00520-022-07098-z
pubmed: 35567609
pmcid: 9106567
Swainston J, Chapman B, Grunfeld EA, Derakshan N. COVID-19 Lockdown and Its Adverse Impact on Psychological Health in Breast Cancer. Front Psychol. 2020;11:2033. https://doi.org/10.3389/fpsyg.2020.02033
DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779–98. https://doi.org/10.1016/j.immuni.2022.09.006 .
doi: 10.1016/j.immuni.2022.09.006
pubmed: 36182669
pmcid: 9468314
Khawaja F, Angelidakis G, Feldman A, Ravi V, Woodman E, Bhatti M, Ariza-Heredia E, Elhajj P, Spallone A, Jiang Y, Chemaly RF. COVID-19 in cancer patients: the impact of vaccination on outcomes early in the pandemic. Cancer Med. 2023 Dec;8. https://doi.org/10.1002/cam4.6781 .
An S, Li Y, Lin Y, et al. Genome-wide profiling reveals alternative polyadenylation of Innate Immune-related mRNA in patients with COVID-19. Front Immunol. 2021;12:756288. https://doi.org/10.3389/fimmu.2021.756288 .
doi: 10.3389/fimmu.2021.756288
pubmed: 34777369
pmcid: 8578971
Wang C, Chen L, Chen Y, et al. Abnormal global alternative RNA splicing in COVID-19 patients. PLoS Genet. 2022;18(4):e1010137. https://doi.org/10.1371/journal.pgen.1010137 .
doi: 10.1371/journal.pgen.1010137
pubmed: 35421082
pmcid: 9089920
Chen Y, Wang G, Li J, et al. CASA: a comprehensive database resource for the COVID-19 Alternative Splicing Atlas. J Transl Med. 2022;20(1):473. https://doi.org/10.1186/s12967-022-03699-8 .
doi: 10.1186/s12967-022-03699-8
pubmed: 36266726
pmcid: 9583055
An S, Xie Z, Liao Y, et al. Systematic analysis of clinical relevance and molecular characterization of m6A in COVID-19 patients. Genes Dis. 2022;9(5):1170–3. https://doi.org/10.1016/j.gendis.2021.12.005 .
doi: 10.1016/j.gendis.2021.12.005
pubmed: 35013711
pmcid: 8730760
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41(10):1037–48.
doi: 10.1002/cac2.12197
pubmed: 34288593
Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond).
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer Nat Rev Dis Primers. 2019;5(1):66.
doi: 10.1038/s41572-019-0111-2
pubmed: 31548545
Guo J, Wei Y, Cen Q, Chen J, Li Y. Developing a novel SARS-CoV-2 risk index to predict the prognostic and therapeutic effects in acute myeloid leukemia. Heliyon. 2023;9(11):e22426. https://doi.org/10.1016/j.heliyon.2023.e22426 .
doi: 10.1016/j.heliyon.2023.e22426
pubmed: 38074856
pmcid: 10700646
Tang Q, Wang Y, Ou L, Li J, Zheng K, Zhan H, Gu J, Zhou G, Xie S, Zhang J, Huang W, Wang S, Wang X. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. Int J Biol Sci. 2021;17(8):1925–39.
doi: 10.7150/ijbs.57802
pubmed: 34131396
pmcid: 8193256
Niu M, Shan M, Liu Y, Song Y, Han JG, Sun S, Liang XS, Zhang GQ. DCTPP1, an Oncogene regulated by miR-378a-3p, promotes proliferation of breast Cancer via DNA repair signaling pathway. Front Oncol. 2021;11:641931. https://doi.org/10.3389/fonc.2021.641931 .
doi: 10.3389/fonc.2021.641931
pubmed: 34113564
pmcid: 8185175
Fan Y, He L, Wang Y, Fu S, Han Y, Fan J, Wen Q. CLIP4 shows putative tumor suppressor characteristics in breast Cancer: an Integrated Analysis. Front Mol Biosci. 2021;7:616190. https://doi.org/10.3389/fmolb.2020.616190 .
doi: 10.3389/fmolb.2020.616190
pubmed: 33575272
pmcid: 7870488
Tang LH, Dai M, Wang DH. ANO6 is a reliable prognostic biomarker and correlates to macrophage polarization in breast cancer. Med (Baltim). 2023;102(45):e36049. https://doi.org/10.1097/MD.0000000000036049 .
doi: 10.1097/MD.0000000000036049
Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: a focus on breast cancer. Semin Cancer Biol. 2019;59:133–46. https://doi.org/10.1016/j.semcancer.2019.08.005 .
doi: 10.1016/j.semcancer.2019.08.005
pubmed: 31408722
Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87–96. https://doi.org/10.1016/j.ctrv.2016.03.004 .
doi: 10.1016/j.ctrv.2016.03.004
pubmed: 26995633
pmcid: 7436195
Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM, Götte M. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, notch and EGFR signaling pathways. Mol Cancer. 2017;16(1):57. https://doi.org/10.1186/s12943-017-0621-z .
doi: 10.1186/s12943-017-0621-z
pubmed: 28270211
pmcid: 5341174
Tao S, Chen Q, Lin C, Dong H. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. J Exp Clin Cancer Res. 2020;39(1):191. https://doi.org/10.1186/s13046-020-01676-x .
doi: 10.1186/s13046-020-01676-x
pubmed: 32943090
pmcid: 7500027
Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics. 2023;13(4):1421–42. https://doi.org/10.7150/thno.81847 .
doi: 10.7150/thno.81847
pubmed: 36923534
pmcid: 10008729
Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC, Hsu HL. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019;18(1):42. https://doi.org/10.1186/s12943-019-0988-0 .
doi: 10.1186/s12943-019-0988-0
pubmed: 30885232
pmcid: 6421700
Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10(1):36. https://doi.org/10.1186/s13045-017-0408-0 .
doi: 10.1186/s13045-017-0408-0
pubmed: 28143526
pmcid: 5286803
Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https://doi.org/10.1038/ncomms3612 .
doi: 10.1038/ncomms3612
pubmed: 24113773
Zhang C, Cheng W, Ren X, et al. Tumor Purity as an underlying key factor in Glioma. Clin Cancer Res. 2017;23(20):6279–91. https://doi.org/10.1158/1078-0432.CCR-16-2598 .
doi: 10.1158/1078-0432.CCR-16-2598
pubmed: 28754819
Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022;31(6):567–91. https://doi.org/10.1080/13543784.2022.2049232 .
doi: 10.1080/13543784.2022.2049232
pubmed: 35240902
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105. https://doi.org/10.1186/s12943-023-01805-y .
doi: 10.1186/s12943-023-01805-y
pubmed: 37415164
pmcid: 10324146
Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol. 2000;165:1352–6.
doi: 10.4049/jimmunol.165.3.1352
pubmed: 10903737
Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19:309–14.
doi: 10.1016/j.coi.2007.04.012
pubmed: 17433872
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1 .
doi: 10.1038/s41591-018-0136-1
pubmed: 30127393
pmcid: 6487502
Zhao J, Luo Z, Fu R, Zhou J, Chen S, Wang J, Chen D, Xie X. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma. Eur J Med Res. 2023;28(1):571.
doi: 10.1186/s40001-023-01535-3
pubmed: 38057871
pmcid: 10698993
Liu Z, Jiang Z, Gao Y, Wang L, Chen C, Wang X. TP53 MutapromoterimmunogenicoactivitytivibreastBcancerCancer. J Oncol. 2019;2019:5952836. https://doi.org/10.1155/2019/5952836 .
doi: 10.1155/2019/5952836
pubmed: 31275382
pmcid: 6582869